Anticancer profile and anti-inflammatory effect of new N-(2-((4-(1,3-diphenyl-1H-pyrazol-4-yl)pyridine sulfonamide derivatives

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Hyuna Sung, Jacques Ferlay, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2021 · 109.5K citations · Full text

Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial

Reinhard Dummer, Paolo A. Ascierto, Helen Gogas et al. · The Lancet Oncology · 2018 · 991 citations · Full text

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

J. Jean Cui, Michelle Tran‐Dubé, Hong Shen et al. · Journal of Medicinal Chemistry · 2011 · 905 citations · Full text

Drug Target, Lead Series, Chemical Biology +20

Synthesis and biological evaluation of some thiazolyl and thiadiazolyl derivatives of 1H-pyrazole as anti-inflammatory antimicrobial agents

Adnan A. Bekhit · European Journal of Medicinal Chemistry · 2007 · 292 citations · Full text

Antifungal Agent, Bioorganic Chemistry, Anti-inflammatory Antimicrobial Agents +7

Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis

John Mascarenhas, Ronald Hoffman · Clinical Cancer Research · 2012 · 231 citations

Antifibrotic Therapy, Mixed-phenotype Acute Leukemia, Immunology +16